CGEM
NASDAQ · Biotechnology
Cullinan Therapeutics Inc
$14.55
-0.17 (-1.15%)
Open$14.61
Previous Close$14.72
Day High$15.20
Day Low$14.30
52W High$16.74
52W Low$5.68
Volume—
Avg Volume870.1K
Market Cap904.56M
P/E Ratio—
EPS$-3.72
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+47.4% upside
Current
$14.55
$14.55
Target
$21.45
$21.45
$16.94
$21.45 avg
$32.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 156.49M | 140.29M | 129.25M |
| Net Income | -25,188,754 | -25,282,384 | -20,083,076 |
| Profit Margin | -16.1% | -18.0% | -15.5% |
| EBITDA | -32,256,643 | -27,830,603 | -25,262,091 |
| Free Cash Flow | -9,992,952 | -10,952,071 | -13,180,515 |
| Rev Growth | +6.1% | +12.8% | -3.3% |
| Debt/Equity | 0.08 | 0.08 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |